<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01646047</url>
  </required_header>
  <id_info>
    <org_study_id>20112190</org_study_id>
    <nct_id>NCT01646047</nct_id>
  </id_info>
  <brief_title>Diabetes Visual Function Supplement Study</brief_title>
  <acronym>DiVFuSS</acronym>
  <official_title>Effects of a Novel Dietary Supplement on Visual Function in Patients With Diabetes With and Without Early Diabetic Retinopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ZeaVision, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ZeaVision, LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the effects of a novel multi-component dietary supplement on the
      visual function and retinal structure of patients with diabetes with both no diabetic
      retinopathy and mild to moderate diabetic retinopathy. This is a placebo-controlled trial and
      neither subjects nor examiners will know if any given subject is taking active supplement or
      placebo.

      The hypothesis is that the supplement will improve visual function and retinal structure in
      subjects on active supplement
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Adult patients with either type 1 or type 2 diabetes will be enrolled with baseline
      measurement of visual acuity, contrast sensitivity, color vision, threshold macular
      perimetry, macular pigment optical density, optical coherence tomography, glycosylated
      hemoglobin, blood lipids and serum vitamin D status. A multi-component dietary supplement
      containing ingredients currently available over the counter in the US will be taken for six
      months and repeat measurements of the above parameters obtained.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in visual function</measure>
    <time_frame>At baseline and again at six months</time_frame>
    <description>Change in contrast sensitivity, color vision and macular perimetry thresholds</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in serum markers</measure>
    <time_frame>At baseline and again at six months</time_frame>
    <description>Changes in glycosylated hemoglobin, serum lipids, serum vitamin D (all subjects) and the serum inflammatory cytokine, tumor necrosis factor-alpha (subjects with retinopathy)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in retinal structure</measure>
    <time_frame>At baseline and again at 6 months</time_frame>
    <description>Changes in optical coherence tomography and macular pigment optical density</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Diabetes Mellitus - Type 1</condition>
  <condition>Diabetes Mellitus - Type 2</condition>
  <condition>Non-proliferative Diabetic Retinopathy</condition>
  <arm_group>
    <arm_group_label>supplement - no retinopathy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>subjects receiving active supplement and with no retinopathy based on clinical examination</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo - no retinopathy</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>patients receiving placebo and who have no diabetic retinopathy based on clinical examination</description>
  </arm_group>
  <arm_group>
    <arm_group_label>supplement - retinopathy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients receiving the active supplement and who have mild to moderate non-proliferative diabetic retinopathy based on clinical examination</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo - retinopathy</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>patients receiving placebo and who have mild to moderate non-proliferative diabetic retinopathy based on clinical examination</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>multi-component nutritional supplement capsules</intervention_name>
    <description>two capsules containing nutritional supplements per day for 6 months (vitamin C, mixed tocopherols/tocotrienols, vitamin D, fish oil, lutein, zeaxanthin, pine bark extract, benfotiamine, green tea extract, curcumin)</description>
    <arm_group_label>supplement - no retinopathy</arm_group_label>
    <arm_group_label>supplement - retinopathy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>multi-component dietary supplement</intervention_name>
    <description>placebo capsules</description>
    <arm_group_label>placebo - no retinopathy</arm_group_label>
    <arm_group_label>placebo - retinopathy</arm_group_label>
    <other_name>two placebo capsules per day for six months</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diabetes mellitus diagnosed at least 5 years

          -  age greater than or equal to 18 years

          -  English speaker

        Exclusion Criteria:

          -  proliferative diabetic retinopathy or severe non-proliferative retinopathy

          -  clinically significant macular edema

          -  corrected visual acuity less than 20/30 in either eye

          -  diagnosis of other serious eye disease (glaucoma, age-related maculopathy)

          -  less than 18 years old

          -  non-English speaker

          -  no known allergy or sensitivity to any supplement ingredients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alan P. Chous, O.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chous Eye Care Associates</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chous Eye Care Associates</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98466</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 3, 2012</study_first_submitted>
  <study_first_submitted_qc>July 17, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 20, 2012</study_first_posted>
  <last_update_submitted>January 20, 2015</last_update_submitted>
  <last_update_submitted_qc>January 20, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 22, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>diabetes</keyword>
  <keyword>diabetic retinopathy</keyword>
  <keyword>nutritional supplements</keyword>
  <keyword>visual function</keyword>
  <keyword>macular pigment</keyword>
  <keyword>macular threshold sensitivity</keyword>
  <keyword>contrast sensitivity</keyword>
  <keyword>color vision</keyword>
  <keyword>optical coherence tomography</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Diabetic Retinopathy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

